GLP-1 Popularity & Usage Stats: Who Benefits Most

Last reviewed: May 27, 2026

Last updated: May 27, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonists now rank among the fastest-growing medication categories in America, with an estimated 10–15 million Americans currently using them as of 2024. This explosive growth—driven by branded products like Ozempic, Wegovy, and Mounjaro—reflects both expanded FDA indications for weight management and significant media coverage around celebrity use and cultural perception.

For patients considering GLP-1 therapy, understanding why adoption has surged and which individuals may benefit most requires more than popularity metrics. PlexusDx takes a precision-wellness approach, examining how metabolic genetics, biomarker patterns, and individual peptide pathway predispositions can inform more personalized discussions with your healthcare provider about whether GLP-1 treatment aligns with your unique physiology.

The Rapid Expansion of GLP-1 Use in the United States

Adoption of GLP-1 medications has accelerated dramatically since 2021. Prescription fills for semaglutide and tirzepatide grew by over 400% in 2023 alone, outpacing most other drug classes. This surge reflects FDA approvals for chronic weight management, widespread telehealth access, and increasing recognition of GLP-1 effects on metabolic health beyond diabetes.

Demographic data reveals that GLP-1 use spans age groups 18–80+, though adoption is highest among adults aged 30–55 with health insurance coverage. Urban and suburban populations access these medications at roughly twice the rate of rural patients, partly due to telehealth infrastructure and pharmacy availability. Commercial insurance claims show tirzepatide now represents approximately 35–40% of new GLP-1 prescriptions, up from less than 5% in 2022.

Patient Profiles and Clinical Eligibility Criteria

GLP-1 medications were originally FDA-approved for type 2 diabetes management and are now approved for chronic weight management in adults with obesity or overweight status plus comorbidities. However, current off-label use extends to patients seeking improved metabolic health, cardiovascular risk reduction, and appetite regulation. Understanding your clinical profile helps determine whether GLP-1 therapy aligns with evidence-based practice guidelines.

Patient Profile Factor	Clinical Considerations
BMI or Weight Status	FDA-approved for BMI ≥30 or ≥27 with weight-related comorbidity; off-label use varies by provider
Type 2 Diabetes or Prediabetes	Strong evidence for glucose control and cardiovascular protection; often first-line therapy
Cardiovascular Risk History	GLP-1 agonists show mortality and MI reduction in large trials; may be prioritized clinically
Gastric Surgery History	Caution with post-bariatric anatomy; compounded dosing allows flexibility not always possible with branded forms
Family History of Thyroid Cancer	Contraindication due to GLP-1 mechanism in rodent studies; requires screening and provider discussion
Kidney or Liver Function	Generally well-tolerated; dose adjustment may be needed with severe impairment or use of other medications
Appetite or GI Baseline	Patients with gastroparesis or chronic GI issues may experience more pronounced nausea; careful titration essential

Genetic Predisposition and Metabolic Response Variations

Not all patients respond identically to GLP-1 therapy. Research increasingly shows that genetic variants in GLP-1 receptor signaling, glucose metabolism, and appetite regulation pathways influence both efficacy and side-effect tolerance. Variants in GLP1R, GIPR, FTO, and MC4R genes may predispose individuals to stronger or weaker appetite suppression and weight loss outcomes.

The PlexusDx Precision Peptide Genetic Test analyzes GLP1R, GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to GLP-1 medications or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Safety, Contraindications, and Provider-Guided Decision-Making

While GLP-1 medications have a favorable long-term safety profile in large trials, they are not appropriate for everyone. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, pregnancy, and severe renal or hepatic disease. Side effects—primarily nausea, vomiting, and constipation—tend to diminish with gradual titration but may limit use in some patients.

Compounded GLP-1 options from licensed 503A pharmacies offer dose flexibility that can support more individualized titration schedules compared to fixed-dose branded versions. However, any decision to initiate GLP-1 therapy, adjust doses, or transition between formulations requires evaluation by a qualified healthcare provider. This includes baseline labs, metabolic history review, and ongoing monitoring. Your provider can weigh adoption trends and popularity against your personal medical profile to determine true clinical appropriateness.

How PlexusDx Supports a More Personalized Approach

PlexusDx Precision Peptide Genetic Test examines variants in key GLP-1 pathway genes—including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313—to reveal your genetic predispositions in peptide signaling and metabolic regulation. These insights may help provide context for understanding why you might respond differently to GLP-1 therapy than national averages suggest, supporting a more informed conversation with your provider about treatment fit.

The genetic test results do not predict exact medication response or guarantee outcomes. Instead, they highlight predispositions in your peptide genetic pathways that should be interpreted alongside your clinical history, current biomarkers, and provider expertise. This holistic view—combining genetics, labs, and clinical judgment—helps move beyond one-size-fits-all approaches that dominate popular GLP-1 discussion.

If you're considering GLP-1 therapy amid rising popularity, requesting the Precision Peptide Genetic Test ($298 standalone or $99 add-on with a GLP-1 prescription) can support a deeper conversation with your healthcare provider about whether GLP-1 aligns with your unique metabolic profile and which compounded formulation (semaglutide injection, oral semaglutide, tirzepatide injection, or oral tirzepatide) and dose strategy may be most appropriate for your pathway predispositions.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral is $349/mo month-to-month, or from $279/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What does the article say about post-bariatric patients considering a GLP-1?

Its patient-profile table flags gastric surgery history as a caution, noting that post-bariatric anatomy requires care and that compounded dosing allows flexibility not always possible with branded forms. The article treats this as one of several factors, alongside BMI, diabetes status and cardiovascular history, that determine whether GLP-1 therapy fits evidence-based practice for a given person.

Why does the article say rural patients use these medications less?

It reports that urban and suburban populations access GLP-1 medications at a notably higher rate than rural patients, and attributes the gap partly to telehealth infrastructure and pharmacy availability rather than to any difference in clinical need. Widespread telehealth access is also listed among the drivers of the broader rise in prescribing since 2021.

Does having gastroparesis or chronic GI issues change what to expect?

The article's table says patients with gastroparesis or chronic GI issues may experience more pronounced nausea and that careful titration is essential in that group. It sits alongside rows on kidney and liver function, where the article notes GLP-1s are generally well tolerated but dose adjustment may be needed with severe impairment or with other medications in play.

What role does the article give compounded options in individualizing treatment?

It says compounded GLP-1 options from licensed 503A pharmacies offer dose flexibility that can support more individualized titration schedules than fixed-dose branded versions. The article is explicit that this flexibility does not change who decides: initiating therapy, adjusting doses or transitioning between formulations all require evaluation by a qualified healthcare provider, including baseline labs and ongoing monitoring.

Which contraindications does the article list for people drawn in by the popularity?

It names a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, pregnancy, and severe renal or hepatic disease. The article's framing is that a favorable long-term safety profile in large trials does not make these medications appropriate for everyone, and that a provider should weigh adoption trends against your personal medical profile.

Related Reading

• Do Genetic Tests Help Identify People Who Will Benefit From Glp 1 Medications
• Glp 1 Medications
• Can A Dna Test Reveal If I Will Benefit From Glp 1 Medications
• Maximus Glp 1

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.